Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06734299 · ClinicalTrials.gov registry record · NA
A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones
A NA study of Sunscreen, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06734299: Completed NA study of Sunscreen, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
NCT06734299 is a NA study of Sunscreen that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06734299, a NA study of Sunscreen, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the whitening potential of different mineral and chemical sunscreens across multi-cultural skin tones through instrumentation, imaging, and self-assessment. It also aimed to evaluate the relationship between self-perception and objective measurements of whitening.
Primary Outcome
Whitening potential of mineral sunscreens across multi-cultural skin tones through instrumentation (Chroma Meter and Polychromatic Hybrid Diffuse Reflectance Spectroscopy measurements) will be reported.
Conditions Studied
Interventions
- OTHER Sunscreen A
- OTHER Sunscreen B
- OTHER Sunscreen C
Study Locations (1)
New Jersey
- SGS North America Inc. - Union Research Center - Union
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-12-06 |
| Est. Completion | 2025-02-14 |
| Phase | NA |
What the finished NCT06734299 record still lists
NCT06734299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Sunscreen appearing as the primary indexed condition, and to 3 interventions - of which Sunscreen A is the first listed.
NCT06734299 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06734299 about?
NCT06734299 is a clinical study titled "A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones". The purpose of the study is to evaluate the whitening potential of different mineral and chemical sunscreens across multi-cultural skin tones through instrumentation, imaging, and self-assessment. It also aimed to evaluate the relationship between self-perception and objective measurements of whiten...
What is the current status of trial NCT06734299?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2024-12-06. Estimated completion is 2025-02-14.
What conditions does trial NCT06734299 study?
This clinical trial studies the following conditions: Sunscreen.
What interventions are being tested in trial NCT06734299?
The interventions under investigation include: Sunscreen A (OTHER), Sunscreen B (OTHER), Sunscreen C (OTHER).
Who is sponsoring clinical trial NCT06734299?
This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06734299 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06734299's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI